Author | Year | N | Population | Gene | Tissue | Methods | Cell | Methylation level in chemoresistant tissue/cell | Expression | Drugs | References |
---|---|---|---|---|---|---|---|---|---|---|---|
Strathdee | 2005 | 41 | UK | MCJ | Advanced EOC | Bisulfite sequencing | – | Hypermethylation | Downregulation | Cisplatin | [24] |
Lee | 2009 | 61 | UK | MAL | SOC | Bisulfite sequencing | – | Hypomethylation | Upregulation | Platinum | [25] |
Watanabe/Gifford | 2007/2004 | 36/138 | Japan/UK | hMLH1 | Advanced EOC | MSP | – | Hypermethylation | Downregulation | Platinum | |
Wang | 2010 | – | – | BRCA1 | – | Bisulfite sequencing | COC1/COC1CisR | Hypomethylation | Upregulation | Cisplatin | [28] |
Chou | 2010 | 96 | China | FBXO32 | OC | MSP | – | Hypermethylation | Downregulation | Cisplatin | [29] |
Nicholson | 2009 | 54 | UK | ASS1 | EOC | Bisulfite sequencing | – | Hypermethylation | Downregulation | Cisplatin | [63] |
GAO | 2019 | – | – | RASSF1A | – | MSP | A2780/A2780CisR | Hypermethylation | Downregulation | Cisplatin | [31] |
GAO | 2019 | – | – | MDR1 | – | MSP | A2780/A2780CisR | Hypomethylation | Upregulation | Cisplatin | [31] |
Dai | 2012 | – | – | PTEN | – | Bisulfite sequencing | OVCAR3 | Hypermethylation | Downregulation | Taxol | [32] |
Li | 2009 | – | – | DR4 | – | MSP | 2008, Hey, NMP-1, OVCAR3, SKOV3, A2780 | Hypermethylation | Downregulation | Platinum | [33] |
Bram | 2009 | – | – | ABCG2 | – | COBRA | IGROV1 | Hypomethylation | Upregulation | Platinum | [34] |
Chiang | 2013 | 136 | China | BLU | Advanced HGSOC | MSP | SKOV3, OVCAR3 | Hypermethylation | Downregulation | Platinum | [35] |
Wang | 2012 | 40 | China | TGFBI | EOC | MSP | SKOV3/SKOV3CisR, SKOV3/TR, A2780/TR | Hypermethylation | Downregulation | Cisplatin and palitaxel | [36] |
Ali | 2013 | – | – | RGS10 | – | Bisulfite sequencing | A2780/A2780CisR, CAOV3, SKOV3 | Hypermethylation | Downregulation | Cisplatin | [37] |
Okochi-Takada | 2006 | 17 | Japan | UCHL1 | OC | MSP | 13 ovarian cancer cell lines | Hypermethylation | Downregulation | Cisplatin | [38] |
Staub | 2007 | – | – | HSulf-1 | – | MSP | SKOV3, OV207 | Hypermethylation | Downregulation | Platinum | [39] |
Su | 2010 | 126 | China | SFRP5 | EOC | MSP | – | Hypermethylation | Downregulation | Cisplatin | [40] |
IZUTSU | 2008 | 66 | Japan | TUBB3 | OC | Bisulfite sequencing | OVCAR-3, JHOC-8 | Hypomethylation | Upregulation | Paclitaxel | [41] |
Pattamadilok | 2008 | 59 | Thailand | LINE-1 | EOC | COBRA | – | Hypomethylation | Unknown | Platinum | [42] |
Jiang | 2014 | – | – | HOXA10 | – | MSP | SKOV3, HEY | Hypomethylation | Upregulation | Platinum | [43] |
Matei | 2012 | 17 | America | HOXA9, HOXA11 | OC | Genome-wide methylation study | – | Hypermethylation | Unknown | Platinum | [44] |
Taniguchi | 2003 | 19 | America | FANCF | OC | MSP | – | Hypomethylation | Upregulation | Cisplatin | [45] |
YANG | 2018 | – | – | OXCT1 | – | Genome-wide methylation study | 8 ovarian cancer cell lines | Hypermethylation | Downregulation | Cisplatin | [46] |
Zhao | 2021 | 483 | GEO and TCGA | AGR2, HSPA2, ACAT2 | SOC | Genome-wide methylation study | – | Hypermethylation | Unknown | Platinum | [47] |
Pan | 2017 | – | – | SERPINE1 | – | MassArray EpiTYPER | A2780CP | Hypomethylation | Upregulation | Carboplatin | [9] |
Zeller | 2012 | – | – | ARMCX2, COL1A1, MDK, MEST | – | Genome-wide methylation study | A2780CisR | Hypermethylation | Downregulation | Cisplatin | [48] |
Ha | 2018 | – | – | NAGA | – | Genome-wide methylation study | 11 ovarian cancer cell lines | Hypermethylation | Downregulation | Cisplatin | [49] |
Visco | 2021 | 16 | America | CLDN1 | Advanced SOC | Genome-wide methylation study | – | Hypomethylation | Upregulation | Cisplatin | [50] |
Bonito | 2016 | 61 | UK | MSX1 | HGSOC | Genome-wide methylation study | – | Hypomethylation | Upregulation | Platinum | [51] |
Tomar | 2016 | – | – | CSK | HGSOC PDXs | Genome-wide methylation study | – | Hypermethylation | Downregulation | Platinum | [52] |
Fang | 2018 | 120 | USA | DOK2 | OC | Genome-wide methylation study | OVCAR3, SKOV3 | Hypermethylation | Downregulation | Platinum | [53] |
Yu | 2011 | – | – | PTK6, PRKCE, BCL2L1 | – | Genome-wide methylation study | A2780CisR | Hypomethylation | Upregulation | Cisplatin | [54] |
Teschendorff | 2015 | 134 | UK | HOTAIR | OC | Genome-wide methylation study | – | Hypomethylation | Upregulation | Platinum | [55] |
Tian | 2019 | 16 | China | hMSH2 | EOC | Bisulfite sequencing | – | Hypermethylation | Downregulation | Platinum | [15] |
Syed | 2011 | 52 | Germany | Plk2 | EOC | MSP | A2780CisR, SKOV3CisR | Hypermethylation | Downregulation | Cisplatin | [56] |
Leon | 2016 | – | – | TMEM88 | OC xenografts | Genome-wide methylation study | – | Hypomethylation | Upregulation | Platinum | [57] |
Mase | 2019 | 78 | Japan/China | ZNF671 | HGSOC | Genome-wide methylation study | JHOS2/4, OVCAR3 | Hypermethylation | Downregulation | Platinum | [58] |
Baba | 2009 | – | – | CD133/PROM1 | – | MSP | OVCAR8/432, A2780, PEO1 | Hypomethylation | Upregulation | Platinum | [59] |
Shang/Litkouhi | 2013/2007 | – | – | CLDN4 | – | MSP | 2008 | Hypermethylation | Downregulation | Cisplatin | |
Witham | 2008 | – | – | DNAJC15 | – | Bisulfite sequencing | OVCAR3/4/5/8, SKOV3 | Hypermethylation | Downregulation | Platinum | [62] |
Kritsch | 2017 | – | – | TRIB2 | – | Genome-wide methylation study | A2780CisR, SKOV3CisR | Hypermethylation | Downregulation | Cisplatin | [10] |
Lund | 2017 | – | – | KLF4 | – | Genome-wide methylation study | M019iCisR, OC002CisR | Hypermethylation | Downregulation | Cisplatin | [11] |
Tomar | 2017 | 45 | Netherlands | FZD10 | HGSOC | Genome-wide methylation study | 10 ovarian cancer cell lines | Hypomethylation | Upregulation | Platinum | [12] |
Vaclavikova | 2019 | 61 | Czech Republic | ABCB1 | EOC | Bisulfite sequencing | – | Hypomethylation | Upregulation | Platinum | [63] |
Yao/Duan | 2004/1999 | – | – | TRAG-3/CSAG2 | – | COBRA | SKOV3 | Hypomethylation | Upregulation | Taxol |